• Explore /
  • Poster
  • / Perioperative chemoimmunotherapy with durvalumab for operable muscle-invasive urothelial carcinoma (MIUC): Primary analysis of the single arm phase II trial SAKK 06/17.

Perioperative chemoimmunotherapy with durvalumab for operable muscle-invasive urothelial carcinoma (MIUC): Primary analysis of the single arm phase II trial SAKK 06/17.

Abstract Poster

Authors

null

Richard Cathomas

Division of Oncology, Cantonal Hospital Graubunden, Chur, Switzerland

Richard Cathomas , Sacha Rothschild , Stefanie Hayoz , Martin Spahn , Berna Özdemir , Bernhard Kiss , Andreas Erdmann , Stefanie Aeppli , Nicolas Mach , Raeto Strebel , Boris A. Hadaschik , Dominik R. Berthold , Miklos Pless , Deborah Zihler , Mathias Schmid , Martina Schneider , Jana Musilova , Ulf Petrausch

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2022 ASCO Annual Meeting

Session Type

Poster Discussion Session

Session Title

Genitourinary Cancer—Kidney and Bladder

Track

Genitourinary Cancer—Kidney and Bladder

Sub Track

Urothelial Cancer - Local-Regional Disease

Clinical Trial Registration Number

NCT03406650

Citation

J Clin Oncol 40, 2022 (suppl 16; abstr 4515)

DOI

10.1200/JCO.2022.40.16_suppl.4515

Abstract #

4515

Poster Bd #

7

Abstract Disclosures

Similar Posters

First Author: Chiara Mercinelli

Poster

2023 ASCO Annual Meeting

NeoPlus: A phase II study of neoadjuvant lenvatinib and pembrolizumab in resectable mucosal melanoma.

NeoPlus: A phase II study of neoadjuvant lenvatinib and pembrolizumab in resectable mucosal melanoma.

First Author: Lili Mao

First Author: Richard Cathomas

First Author: Lisanne P. Zijlker